|
1H4L
Structure and regulation of the CDK5-p25(nck5a) complex
Deposited 2001-05-11
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
147–293(147 aa)
Fragment:RESIDUES 147-293
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;293 K;MICROSEEDING - PEG3350, 100 MM TRIS PH 7.6, 200 MM KI, 10 MM DTT, PROTEIN CONC.:7 MG/ML HANGING DROP 2+2 UL. TEMPERATURE 293K.
|
Resolution 2.65 Å
R-free 0.287
|
|
1H4L
Structure and regulation of the CDK5-p25(nck5a) complex
Deposited 2001-05-11
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
147–293(147 aa)
Fragment:RESIDUES 147-293
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;293 K;MICROSEEDING - PEG3350, 100 MM TRIS PH 7.6, 200 MM KI, 10 MM DTT, PROTEIN CONC.:7 MG/ML HANGING DROP 2+2 UL. TEMPERATURE 293K.
|
Resolution 2.65 Å
R-free 0.287
|
|
1UNG
Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Not recorded
|
ALH 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1M KI, 0.1M BISTRISPROPANE PH 7.0, 10MM DTT
|
Resolution 2.30 Å
R-free 0.225
|
|
1UNG
Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Not recorded
|
ALH 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1M KI, 0.1M BISTRISPROPANE PH 7.0, 10MM DTT
|
Resolution 2.30 Å
R-free 0.225
|
|
1UNH
Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Not recorded
|
IXM (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1 M KI 0.1 M BISTRISPROPANE PH 7.0, 10 MM DTT
|
Resolution 2.35 Å
R-free 0.230
|
|
1UNH
Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Not recorded
|
IXM (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1 M KI 0.1 M BISTRISPROPANE PH 7.0, 10 MM DTT
|
Resolution 2.35 Å
R-free 0.230
|
|
1UNL
Structural mechanism for the inhibition of CD5-p25 from the roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Mutation:YES
|
RRC R-ROSCOVITINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1 M KI, 0.1 M BISTRISPROPANE PH 7.0, 10 MM DTT
|
Resolution 2.20 Å
R-free 0.219
|
|
1UNL
Structural mechanism for the inhibition of CD5-p25 from the roscovitine, aloisine and indirubin.
Deposited 2003-09-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
100–307(208 aa)
Fragment:RESIDUES 100-307
|
Mutation:YES
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;13% PEG 3350, 0.1 M KI, 0.1 M BISTRISPROPANE PH 7.0, 10 MM DTT
|
Resolution 2.20 Å
R-free 0.219
|
|
3O0G
Crystal Structure of Cdk5:p25 in complex with an ATP analogue
Deposited 2010-07-19
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
145–293(149 aa)
Fragment:UNP residues 146-293
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;293 K;PEG 3350, KI, Bis-Tris Propane, pH 7, vapor diffusion, temperature 293K
|
Resolution 1.95 Å
R-free 0.256
|
|
3O0G
Crystal Structure of Cdk5:p25 in complex with an ATP analogue
Deposited 2010-07-19
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
145–293(149 aa)
Fragment:UNP residues 146-293
|
Not recorded
|
3O0 {4-amino-2-[(4-chlorophenyl)amino]-1,3-thiazol-5-yl}(3-nitrophenyl)methanone × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;293 K;PEG 3350, KI, Bis-Tris Propane, pH 7, vapor diffusion, temperature 293K
|
Resolution 1.95 Å
R-free 0.256
|
|
6LDP
Structure of CDK5R1-bound FEM1C
Deposited 2019-11-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
298–307(10 aa)
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.2M Lithium sulfate, 0.1M Tris-Hcl pH 7.9
|
Resolution 2.35 Å
R-free 0.258
|
|
6LDP
Structure of CDK5R1-bound FEM1C
Deposited 2019-11-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
298–307(10 aa)
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.2M Lithium sulfate, 0.1M Tris-Hcl pH 7.9
|
Resolution 2.35 Å
R-free 0.258
|
|
7CNG
Structure of CDK5R1 bound FEM1B
Deposited 2020-07-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
298–307(10 aa)
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;1.6M Magnesium sulfate hydrate, 0.1M BIS-TRIS propane pH 6.7
|
Resolution 3.49 Å
R-free 0.267
|
|
7CNG
Structure of CDK5R1 bound FEM1B
Deposited 2020-07-31
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
298–307(10 aa)
|
Not recorded
|
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;1.6M Magnesium sulfate hydrate, 0.1M BIS-TRIS propane pH 6.7
|
Resolution 3.49 Å
R-free 0.267
|
|
7VDP
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 1
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
100–307(208 aa)
|
Not recorded
|
65L [1-[3-fluoranyl-4-[(2-piperidin-4-yloxy-1,6-naphthyridin-7-yl)amino]phenyl]pyrazol-3-yl]methanol × 1
EDO 1,2-ETHANEDIOL × 10
PEG DI(HYDROXYETHYL)ETHER × 2
CL CHLORIDE ION × 7
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 2.09 Å
R-free 0.229
|
|
7VDP
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 1
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
|
Not recorded
|
65L [1-[3-fluoranyl-4-[(2-piperidin-4-yloxy-1,6-naphthyridin-7-yl)amino]phenyl]pyrazol-3-yl]methanol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 2.09 Å
R-free 0.229
|
|
7VDQ
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 7
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
100–307(208 aa)
|
Not recorded
|
64V 2-[[7-[[2-fluoranyl-4-[3-(hydroxymethyl)pyrazol-1-yl]phenyl]amino]-1,6-naphthyridin-2-yl]-(1-methylpiperidin-4-yl)amino]ethanoic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 2.91 Å
R-free 0.284
|
|
7VDQ
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 7
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
|
Not recorded
|
64V 2-[[7-[[2-fluoranyl-4-[3-(hydroxymethyl)pyrazol-1-yl]phenyl]amino]-1,6-naphthyridin-2-yl]-(1-methylpiperidin-4-yl)amino]ethanoic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 2.91 Å
R-free 0.284
|
|
7VDS
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 24
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
100–307(208 aa)
|
Not recorded
|
61U 5-fluoranyl-4-[[2-[(1R)-1-(1-methylpiperidin-4-yl)-1-oxidanyl-ethyl]-1,6-naphthyridin-7-yl]amino]-2-morpholin-4-yl-benzenecarbonitrile × 1
GOL GLYCEROL × 8
EDO 1,2-ETHANEDIOL × 17
CL CHLORIDE ION × 19
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 3.05 Å
R-free 0.272
|
|
7VDS
The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 24
Deposited 2021-09-07
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
100–307(208 aa)
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;291 K;0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350
|
Resolution 3.05 Å
R-free 0.272
|